HAYASHI, Tetsutaro

論文

  1. Kobayashi G, Sentani K, Babasaki T, Sekino Y, Shigematsu Y, Hayashi T, Oue N, Teishima J, Matsubara A, Sasaki N, Yasui W.
    Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma.
    Cancer Sci. 2020 Jan 7. doi: 10.1111/cas.14299. [Epub ahead of print]
    Abstract:パブメドGoogle ScholarIF:
  2. Han X, Sekino Y, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Sakamoto N, Sentani K, Oue N, Yasui W, Matsubara A.
    Microtubule-associated Protein Tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma.
    Urol Oncol. 2020 Mar 2. pii: S1078-1439(20)30051-X.
    Abstract:パブメドGoogle ScholarIF:
  3. Teishima J, Murata D, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S, Matsubara A.
    Improved prognosis for older-aged patients with metastatic renal cell carcinoma after targeted therapy.
    Mol Clin Oncol, 12: 557-564, 2020.
    Abstract:パブメドGoogle ScholarIF:
  4. Yamanaka R, Sekino Y, Babasaki T, Kitano H, Ikeda K, Goto K, Hieda K, Inoue S, Hayashi T, Teishima J, Aikata H, Chayama K, Sentani K, Yasui W, Matsubara A.
    Renal Metastasis from Primary Hepatocellular Carcinoma: A case report.
    Int Cancer Conf J, Mar 25, 2020, Epub.
    Abstract:パブメドGoogle ScholarIF:
  5. Sekino Y, Hagura T, Han X, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shigeta M, Taniyama D, Kuraoka K, Sentani K, Yasui W,Matsubara A.
    PTEN is involved in sunitinib and sorafenib resistance in renal cell carcinoma.
    Anticancer Res 40:1943-1951, 2020.
    Abstract:パブメドGoogle ScholarIF:
  6. Inoue S, Hayashi T, Teishima J, Matsubara A.
    Comparative analysis of robot-assisted, laparoscopic, and open radical prostatectomy regarding lower urinary tract symptoms: A longitudinal study.
    Urol Sci 31(1): 21-27, 2020.
    Abstract:パブメドGoogle ScholarIF:
  7. Inoue S, Hayashi T, Teishima J, Matsubara A.
    Prevalence of hand joint symptoms in androgen deprivation therapy among Japanese patients with prostate cancer.
    Urol Sci 31(1): 15-20, 2020.
    Abstract:パブメドGoogle ScholarIF:
  8. Sekino Y, Han X, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Takeshima Y, Yasui W, Matsubara A.
    Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
    Urol Oncol. 2020 May 16: S1078-1439(20): 30191-30195, 2020.
    Abstract:パブメドGoogle ScholarIF:
  9. Sekino Y, Han X, Babasaki T, Miyamoto S, Kitano H, Kobayashi G, Goto K, Inoue S, Hayashi T, Teishima J, Sakamoto N, Sentani K, Oue N, Yasui W, Matsubara A.
    TUBB3 is associated with high-grade histology, poor prognosis, p53 expression, and cancer stem cell markers in clear cell renal cell carcinoma.
    Oncology, in press.
    Abstract:パブメドGoogle ScholarIF:
  10. Teishima J, Murata D, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S and Matsubara A.
    Prediction for early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor.
    Curr Urol, in press.
    Abstract:パブメドGoogle ScholarIF:
  11. Teishima J, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S, Matsubara A.
    Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with 1st line tyrosine kinase inhibitors.
    Can Urol Assoc J, in press.
    Abstract:パブメドGoogle ScholarIF:
  12. Inoue S, Hayashi T, Teishima J, Matsubara A.
    Impact of adrenalectomy on cortisol-producing adenoma: longitudinal evaluation of health-related quality of life following laparoscopic adrenalectomy.
    Urol Int, in press.
    Abstract:パブメドGoogle ScholarIF:
  13. Inoue S, Hayashi T, Teishima J, Matsubara A.
    Effect of penile rehabilitation with low-intensity extracorporeal shock wave therapy on erectile function recovery following robot-assisted radical prostatectomy.
    Translational Andrology and Urology, in press.
    Abstract:パブメドGoogle ScholarIF:
  14. Fujii S, Hayashi T, Honda Y, Terada H, Akita R, Kitamura N, Ueda E, Han X, Ueno T, Miyamoto S, Kitano H, Inoue S, Teishima J, Abdi H, Awai K, Takeshima Y, Sentani K, Yasui W, Matsubara A.
    Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naïve Japanese men compared with the standard biopsy.
    Int J Urol. 2020 Feb;27(2):140-146. doi: 10.1111/iju.14149. Epub 2019 Nov 16.
    Abstract:パブメドGoogle ScholarIF:
  15. Honda Y, Nakamura Y, Teishima J, Goto K, Higaki T, Narita K, Akagi M, Terada H, Kaichi Y, Fujii S, Hayashi T, Matsubara A, Sentani K, Yasui W,
    Clinical staging of upper urinary tract urothelial carcinoma for T staging: Review and pictorial essay.
    Int J Urol. 2019 Nov;26(11):1024-1032. doi: 10.1111/iju.14068. Epub 2019 Aug 4.
    Abstract:パブメドGoogle ScholarIF:
  16. Kenichiro Fukuoka,Jun Teishima,Hirotaka Nagamatsu,Shogo Inoue,Tetsutaro Hayashi,Koji Mita,Masanobu Shigeta,Kanao Kobayashi,Mitsuru Kajiwara,Yuichi Kadonishi,Takatoshi Tacho,Akio Matsubara.
    Predictors of poor response to first‐generation anti‐androgens
as criteria for alternate treatments for patients with non‐metastatic castration‐resistant prostate cancer.
    International Urology and Nephrology https://doi.org/10.1007/s11255-019-02281-4. Received: 21 June 2019 / Accepted: 10 September 2019
    Abstract:パブメドGoogle ScholarIF:
  17. Mukai S, Shinmei S, Muto M, Hatayama T, Shikuma H, Miyamoto S, Fujii S, Sadahide K, Sekino Y, Hieda K, Inoue S, Hayashi T, Teishima J, Matsubara A.
    Refractory fistula of bladder repaired with transurethral cystoscopic injection of N‐butyl‐2‐cyanoacrylate.
    IJU Case Rep, 2019. https://doi.org/10.1002/iju5.12130
    Abstract:パブメドGoogle ScholarIF:
  18. Shikuma H, Inoue S, Hatayama T, Mukai S, Muto M, Miyamoto S, Sadahide K, Fujii S, Sekino Y, Goto K, Shinmei S, Hieda K, Hayashi T, Teishima J, Matsubara A.
    Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinoma.
    IJU Case Rep, 2019. https://doi.org/10.1002/iju5.12119
    Abstract:パブメドGoogle ScholarIF:
  19. Hatayama T, Sekino Y, Shikuma H, Mukai S, Muto M, Miyamoto S, Sadahide K, Fukuoka K, Fujii S, Goto K, Shinmei S, Hieda K, Inoue S, Hayashi T, Teishima J, Kuroda N, Sentani K, Yasui W, Matsubara A.
    Case of renal mucinous tubular and spindle cell carcinoma with high nuclear grade.
    IJU Case Rep 2 (4), 2019. https://doi.org/10.1002/iju5.12075
    Abstract:パブメドGoogle ScholarIF:
  20. Teishima J, Inoue S, Hayashi T, Matsubara A.
    Current status of prognostic factors in patients with metastatic renal cell carcinoma.
    Int J Urol, 26(6):608-617, 2019
    Abstract:パブメドGoogle ScholarIF:
  21. Sekino Y, Sakamoto N, Ishikawa A, Honma R, Shigematsu Y, Hayashi T, Sentani K, Oue N, Teishima J, Matsubara A, Yasui W.
    Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
    Oncol Rep. 2019 Feb 28. doi: 10.3892/or.2019.7039. [Epub ahead of print]
    Abstract:パブメドGoogle ScholarIF:
  22. Sekino Y, Oue N, Mukai S, Shigematsu Y, Goto K, Sakamoto N, Sentani K, Hayashi T, Teishima J, Matsubara A, Yasui W.
    Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
    Prostate. 2019 Feb;79(2):234-242. doi: 10.1002/pros.23728. Epub 2018 Oct 16.
    Abstract:パブメドGoogle ScholarIF:
  23. Sekino Y, Han X, Kawaguchi T, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Yasui W, Matsubara A.
    TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
    Int J Mol Sci. 2019 Aug 13;20(16). pii: E3936. doi: 10.3390/ijms20163936.
    Abstract:パブメドGoogle ScholarIF:
  24. Inoue S, Hayashi T, Hieda K, Shinmei S, Teishima J, Matsubara A.
    Longitudinal analysis of laparoendoscopic single-site adrenalectomy and conventional laparoscopic adrenalectomy regarding patient-reported satisfaction and cosmesis outcomes.
    Asian J Surg. 2019 Mar;42(3):514-519. doi: 10.1016/j.asjsur.2018.10.002. Epub 2018 Nov 13.
    Abstract:パブメドGoogle ScholarIF:
  25. Teishima J, Hayashi T, Nagamatsu H, Shoji K, Shikuma H, Yamanaka R, Sekino Y, Goto K, Inoue S, Matsubara A.
    Fibroblast Growth Factor Family in the Progression of Prostate Cancer.
    J Clin Med.2019 Feb 4;8(2) doi:10.3390/jcm8020183.
    Abstract:パブメドGoogle ScholarIF:
  26. Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Ladhar S, Kamjabi A, Al Nakouzi N, Hayashi T, Choi S, Wang Y, Frees S, Daugaard M, Oo HZ1, Fisel P, Schwab M, Schaeffeler E, Douglas J, Hennenlotter J, Bedke J, Gibb EA, Fazli L, Stenzl , Black PC.
    Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
    Mol Cancer Ther. 2018 Dec;17(12):2746-2755. doi: 10.1158/1535-7163.MCT-18-0107. Epub 2018 Sep 27."
    Abstract:パブメドGoogle ScholarIF:
  27. Yuki Kohada, Tetsutaro Hayashi, Keisuke Goto, Kohei Kobatake, Hamidreza Abdi, Yukiko Honda, Kazuhiro Sentani, Shogo Inoue,Jun Teishima, Kazuo Awai, Wataru Yasui, and Akio Matsubara.
    Preoperative risk classification using neutrophil-lymphocyte ratio and hydronephrosis for upper tract urothelial carcinoma.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 2018 Sep-18 28(9) 841-849 10.1093/jjco/hyy084
    Abstract:パブメドGoogle ScholarIF:
  28. Akihiro Goriki, Roland Seiler, Alexander W. Wyatt, Alberto Contreras-Sanz, Akshay Bhat, Akio Matsubara, Tetsutaro Hayashi & Peter C. Black.
    Unravelling disparate roles of NOTCH in bladder cancer.
    NATURE REVIEWS UROLOGY Jun-18 15(6) 345-357 10.1038/s41585-018-0005-1
    Abstract:パブメドGoogle ScholarIF:
  29. Teishima J, Ohara S, Shinmei S, Inoue S, Hayashi T, Mochizuki H, Mita K, Shigeta M, Matsubara A.
    Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Urol Oncol. 2018 May 14. pii: S1078-1439(18)30130-3. doi: 10.1016/j.urolonc.2018.04.008. [Epub ahead of print]
    Abstract:パブメドGoogle ScholarIF:
  30. Kishida N, Sentani K, Terada H, Honda Y, Goto K, Hatanaka Y, Kohashi K, Oda Y, Iwata J, Yasui W, Shinmei S, Hayashi T, Teishima J, Matsubara A, Nakamura Y, Iida M, Awai K.
    Anastomosing haemangioma with fatty changes in the perirenal space: a lesion mimicking liposarcoma.
    BJR Case Rep. 2017 Nov 1;4(2):20170022. doi: 10.1259/bjrcr.20170022. eCollection 2018.
    Abstract:パブメドGoogle ScholarIF:
  31. Yukiko Honda , Yuko Nakamura, Keisuke Goto, Hiroaki Terada, Kazuhiro Sentani,Wataru Yasui, Yohei Sekino, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara,Motonori Akagi, Tomoyo Fuji, Yasutaka Baba, Makoto Iida, and Kazuo Awai.
    Tubulocystic renal cell carcinoma: a review of literature focused on radiological findings for differential diagnosis.
    ABDOMINAL RADIOLOGY 2018 Jul-18 43(7) 1540-1545 10.1007/s00261-018-1643-8
    Abstract:パブメドGoogle ScholarIF:
  32. Bernhard Kiss, Alexander W. Wyatt, James Douglas, Veronika Skuginna,Fan Mo, Shawn Anderson, Diana Rotzer, Achim Fleischmann, Vera Genitsch,Tetsutaro Hayashi, Maja Neuenschwander, Christine Buerki, Elai Davicioni, Colin Collins, George N. Thalmann, Peter C. Black & Roland Seiler.
    Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.
    Sci Rep. 2017 Feb 16;7:42713. doi: 10.1038/srep42713.
    Abstract:パブメドGoogle ScholarIF:
  33. Honda Y, Goto K, Nakamura Y, Terada H, Sentani K, Yasui W, Sekino Y, Hayashi T, Teishima J, Matsubara A, Fuji T, Kaichi Y, Higaki T, Baba Y, Iida M, Awai K.
    Imaging features of papillary renal cell carcinoma with cystic change-dominant appearance in the era of the 2016 WHO classification.
    Abdom Radiol (NY). 2017 Jul;42(7):1850-1856.
    Abstract:パブメドGoogle ScholarIF:
  34. Shoji K, Teishima J, Hayashi T, Shinmei S, Akita T, Sentani K, Takeshima Y, Arihiro K, Tanaka J, Yasui W, Matsubara A.
    A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients.
    Oncol Lett. 2017 Jul;14(1):299-305. doi: 10.3892/ol.2017.6119. Epub 2017 May 4.
    Abstract:パブメドGoogle ScholarIF:
  35. Kobatake K, Hayashi T, Black PC, Goto K, Sentani K, Kaneko M, Yasui W, Mita K, Teishima J, Matsubara A.
    Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Int J Urol. 2017 Aug;24(8):594-600.
    Abstract:パブメドGoogle ScholarIF:
  36. Kitano H, Kitadai Y, Teishima J, Yuge R, Shinmei S, Goto K, Inoue S, Hayashi T, Sentani K, Yasui W, Matsubara A.
    Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.
    Cancer Med.2017 Oct;6(10)2308-2320
    Abstract:パブメドGoogle ScholarIF:
  37. Jun Teishima, Kohei Kobatake,Shunsuke Shinmei, Shogo Inoue, Tetsutaro Hayashi, Shinya Ohara,Koji Mita,Yasuhisa Hasegawa, Satoshi Maruyama, Mitsuru Kajiwara, Masanobu Shigeta, Hideki Mochizuki,Hiroyuki Moriyama,Seiji Fujiwara,Akio Matsubara.
    The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
    Urol Oncol. 2017 Nov;35(11):662.e1-662.e7. doi: 10.1016/j.urolonc.2017.07.008. Epub 2017 Aug 1.
    Abstract:パブメドGoogle ScholarIF:
  38. Teishima J, Ohara S, Sadahide K, Fujii S, Kitano H, Kobatake K, Shinmei S, Hieda K, Inoue S, Hayashi T, Mita Matsubara A.
    Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis.
    CUAJ • May 2017 • Volume 11, Issue 5.
    Abstract:パブメドGoogle ScholarIF:
  39. Inoue S, Kurimura Y, Sadahide K, Hayashi T, Teishima J, Higashi Y, Matsubara A.
    Low-intensity extracorporeal shock wave therapy for patients with severe erectile dysfunction due to radical prostatectomy.
    Ann Res Hosp 2017;1:2 doi: 10.21037/arh.2017.04.02
    Abstract:パブメドGoogle ScholarIF:
  40. Kiss B, Wyatt AW, Douglas J, Skuginna V, Mo F, Anderson S, Rotzer D, Fleischmann A, Genitsch V, Hayashi T, Neuenschwander M, Buerki C, Davicioni E, Collins C, Thalmann GN, Black PC, Seiler R.
    Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.
    Sci Rep. 2017 Feb 16;7:42713. doi: 10.1038/srep42713.
    Abstract:パブメドGoogle ScholarIF:
  41. Kohada Y, Teishima J,Hattori Y, Kurimura Y, Fujii S, Sadahide K, Fukuoka K, Ueno T, Kitano H, Goto K, Hieda K, Shinmei S, Sentani K, Inoue S, Hayashi T, Yasui W, Matsubara A.
    Serous adenocarcinoma of retroperitoneum: a case report.
    Int Canc Conf J. 2017,doi: 10.1007/s13691-017-0296-8
    Abstract:パブメドGoogle ScholarIF:
  42. Hayashi T, Gust KM, Wyatt AW, Goriki A, Jäger W, Awrey S, Li N, Oo HZ, Altamirano-Dimas M, Buttyan R, Fazli L, Matsubara A, Black PC.
    Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy.
    Clin Cancer Res. 2016 Jan 14. [Epub ahead of print]
    Abstract:パブメドGoogle ScholarIF:
  43. Maeda Y, Goto K, Honda Y, Kuroda N, Sentani K, Yasui W, Hayashi T, Teishima J, Matsubara A, Nakamura Y, Toyota N, Iida M, Awai K.
    A case of tubulocystic carcinoma of the kidney with aggressive features.
    Jpn J Radiol. 2016 Apr;34(4):307-11. doi: 10.1007/s11604-016-0525-7.
    Abstract:パブメドGoogle ScholarIF:
  44. Hayashi T, Seiler R, Oo HZ, Jäger W, Moskalev I, Awrey S, Dejima T, Todenhöfer T, Li N, Fazli L, Matsubara A, Black PC.
    Targeting HER2 with T-DM1, an Antibody-cytotoxic Drug Conjugate, is effective in HER2-overexpressing bladder cancer.
    J Urol. 2015 Oct;194(4):1120-31. doi: 10.1016/j.juro.2015.05.087.
    Abstract:パブメドGoogle ScholarIF:
  45. Teishima J, Kobatake K, Kitano H, Nagamatsu H, Sadahide K, Hieda K, Shinmei S, Shoji K, Inoue S, Hayashi T, Inoue Y, Ohara S, Mita K, Matsubara A.
    The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma.
    BJU Int. 2015 Aug 25. doi: 10.1111/bju.13260.
    Abstract:パブメドGoogle ScholarIF:
  46. Teishima J, Yano S, Shoji K, Hayashi T, Goto K, Kitano H, Oka K, Nagamatsu H, Matsubara A.
    Accumulation of FGF9 in prostate cancer correlates with epithelial-to-mesenchymal transition and induction of VEGF-A expression.
    Anticancer Res. 2014 Feb;34(2):695-700.
    Abstract:パブメドGoogle ScholarIF:
  47. Shoji K, Teishima J, Hayashi T, Ohara S, Mckeehan WL, Matsubara A.
    Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells.
    Oncol Rep. 2014 Jul;32(1):65-70. doi: 10.3892/or.2014.3200.
    Abstract:パブメドGoogle ScholarIF:
  48. Teishima J, Kobatake K, Hayashi T, Seno Y, Ikeda K, Nagamatsu H, Hieda K, Shoji K, Miyamoto K, Inoue S, Kobayashi K, Ohara S, Kajiwara M, Matsubara A.
    Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy.
    Oncol Lett. 2014 Aug;8(2):881-885.
    Abstract:パブメドGoogle ScholarIF:
  49. Shinmei S, Sentani K, Hayashi T, Sakamoto N, Goto K, Zarni Oo H, Naito Y, Teishima J, Matsubara A, Oue N, Kuniyasu H, Yasui W.
    Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method.
    Urol Oncol. 2014 Aug;32(6):769-78. doi: 10.1016/j.urolonc.2014.03.007.
    Abstract:パブメドGoogle ScholarIF:
  50. Goto K, Oue N, Hayashi T, Shinmei S, Sakamoto N, Sentani K, Teishima J, Matsubara A, Yasui W.
    Oligophrenin-1 is associated with cell adhesion and migration in prostate cancer.
    Pathobiology. 2014;81(4):190-8. doi: 10.1159/000363345.
    Abstract:パブメドGoogle ScholarIF:
  51. Shinmei S, Sakamoto N, Goto K, Sentani K, Anami K, Hayashi T, Teishima J, Matsubara A, Oue N, Kitadai Y, Yasui W.
    MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma.
    Int J Urol. 2013 May;20(5):468-77. doi: 10.1111/j.1442-2042.2012.03182.x.
    Abstract:パブメドGoogle ScholarIF:
  52. Hayashi T, Sentani K, Oue N, Ohara S, Teishima J, Anami K, Sakamoto N, Matsubara A, Yasui W.
    The search for secreted proteins in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of NBL1 is highly restricted to the prostate and is related to cancer progression.
    Pathobiology. 2013;80(2):60-9. doi: 10.1159/000341396.
    Abstract:パブメドGoogle ScholarIF:
  53. Goto K, Oue N, Shinmei S, Sentani K, Sakamoto N, Naito Y, Hayashi T, Teishima J, Matsubara A and Yasui W
    Expression of miR-486 is a potential prognostic factor after nephrectomy in advanced renal cell carcinoma.
    Mol Clin Oncol 1:235-240, 2013
    Abstract:パブメドGoogle ScholarIF:
  54. Teishima J, Hattori M, Inoue S, Ikeda K, Hieda K, Miyamoto K, Shoji K, Hayashi T, Kobayashi K, Kajiwara M, Egi H, Ohdan H, Matsubara A.
    Impact of laparoscopic experience on the proficiency gain of urologic surgeons in robot-assisted surgery.
    J Endourol. 2012 Dec;26(12):1635-8. doi: 10.1089/end.2012.0308.
    Abstract:パブメドGoogle ScholarIF:
  55. Teishima J, Shoji K, Hayashi T, Miyamoto K, Ohara S, Matsubara A.
    Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence.
    Prostate Cancer Prostatic Dis. 2012 Mar;15(1):8-14. doi: 10.1038/pcan.2011.48.
    Abstract:パブメドGoogle ScholarIF:
  56. Hayashi T, Oue N, Sakamoto N, Anami K, Oo HZ, Sentani K, Ohara S, Teishima J, Matsubara A, Yasui W.
    Identification of transmembrane protein in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of CDON is involved in tumor cell growth and invasion.
    Pathobiology. 2011;78(5):277-84. doi: 10.1159/000329588.
    Abstract:パブメドGoogle ScholarIF:
  57. Hayashi T, Sentani K, Oue N, Anami K, Sakamoto N, Ohara S, Teishima J, Noguchi T, Nakayama H, Taniyama K, Matsubara A, Yasui W.
    Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinoma.
    Histopathology. 2011 Oct;59(4):710-21. doi: 10.1111/j.1365-2559.2011.03988.x.
    Abstract:パブメドGoogle ScholarIF:
  58. Hayashi T, Matsubara A, Ohara S, Mita K, Hasegawa Y, Usui T, Arihiro K, Norimura S, Sentani K, Oue N, Yasui W.
    Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker.
    Oncol Rep. 2009 Jan;21(1):95-100.
    Abstract:パブメドGoogle ScholarIF:
  59. Ohara S, Matsubara A, Mita K, Hasegawa Y, Hayashi T, Usui T, Takeshima Y, Kuniyasu H, Oue N, Yasui W.
    Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer.
    Cancer Sci. 2008 Aug;99(8):1570-7. doi: 10.1111/j.1349-7006.2008.00846.x.
    Abstract:パブメドGoogle ScholarIF:
  60. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, Anderson S, Moskalev I, Haegert A, Alshalalfa M, Erho N, Davicioni E, Fazli L, Li E, Collins C, Wang Y, Black PC
    Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
    Oncotarget. 2015 May 27.
    Abstract:パブメドGoogle ScholarIF:
  61. Anami K, Oue N, Noguchi T, Sakamoto N, Sentani K, Hayashi T, Naito Y, Oo HZ, Yasui W
    TSPAN8, identified by Escherichia coli ampicillin secretion trap, is associated with cell growth and invasion in gastric cancer.
    Gastric Cancer. 2015 Feb 25.
    Abstract:パブメドGoogle ScholarIF:
  62. Jäger W, Moskalev I, Janssen C, Hayashi T, Gust KM, Awrey S, Black PC
    Minimally invasive establishment of murine orthotopic bladder xenografts.
    J Vis Exp. 2014 Feb 11;(84):e51123. doi: 10.3791/51123.
    Abstract:パブメドGoogle ScholarIF:
  63. Oue N, Naito Y, Hayashi T, Takigahira M, Kawano-Nagatsuma A, Sentani K, Sakamoto N, Zarni Oo H, Uraoka N, Yanagihara K, Ochiai A, Sasaki H, Yasui W
    Signal peptidase complex 18, encoded by SEC11A, contributes to progression via TGF-α secretion in gastric cancer.
    Oncogene. 2013 Sep 2. doi: 10.1038/onc.2013.364.
    Abstract:パブメドGoogle ScholarIF:
  64. Jäger W, Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, Hadaschik BA, Matsui Y, Anderson S, Bell RH, Ettinger S, So AI, Gleave ME, Lee IL, Dinney CP, Tachibana M, McConkey DJ, Black PC
    Hiding in plain view: Genetic profiling reveals decades old cross-contamination of bladder cancer cell line KU7 with HeLa.
    J Urol. 190:1404-9, 2013
    Abstract:パブメドGoogle ScholarIF:
  65. Jäger W, Moskalev I, Janssen C, Hayashi T, Awrey S, Kilian KM, So AI, Zhang K, Fazli L, Li E, Thüroff JW, Lange D, Black PC
    Ultrasound-Guided Intramural Inoculation of Orthotopic Bladder Cancer Xenografts: A Novel High-Precision Approach.
    PLoS ONE 2013; 8: e59536.
    Abstract:パブメドGoogle ScholarIF:
  66. Inoue Y, Goto K, Hayashi T, Hayashi M
    Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer.
    Int J Urol 18:358-63, 2011.
    Abstract:パブメドGoogle ScholarIF:
  67. Anami K, Oue N, Noguchi T, Sakamoto N, Sentani K, Hayashi T, Hinoi T, Okajima M, Graff JM and Yasui W
    Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: expression of DSC2 in gastric cancer with intestinal phenotype.
    J Pathol 221:275-284, 2010
    Abstract:パブメドGoogle ScholarIF:
  68. Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, Anami K, Motoshita J, Ito M, Tanaka S, Yoshida K and Yasui W
    Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients.
    Int J Cancer 125:2382-2392, 2009
    Abstract:パブメドGoogle ScholarIF:
  69. 亭島 淳, 井上 省吾, 稗田 圭介, 神明 俊輔, 林 哲太郎, 松原 昭郎
    進化しつつある腎細胞がん治療-プレシジョンメディスンに向けて- ロボット支援腎部分切除術 症例ごとの最適な対応(解説) 日本腎泌尿器疾患予防医学研究会誌 2018 26(1) 39-42
    Abstract:パブメドGoogle ScholarIF:
  70. 林 哲太郎, 神明 俊輔, 後藤 景介, 稗田 圭介, 井上 省吾, 亭島 淳, 松原 昭郎
    泌尿器がんにおける抗体薬物複合体治療の可能性 西日本泌尿器科 2018 80(11) 567-571
    Google ScholarIF:
  71. 西田 健介, 藤井 慎介, 林 哲太郎, 上野 剛志, 岩根 亨輔, 田坂 亮, 栗村 嘉昌, 定秀 孝介, 福岡 憲一郎, 稗田 圭介, 神明 俊輔, 井上 省吾, 亭島 淳, 松原 昭郎
    MRI-TRUS融合画像リアルタイムガイド下前立腺生検の有用性 狙撃生検は診断精度を向上させる 泌尿器外科 2018 31(8) 1197-1200
    Google ScholarIF:
  72. 亭島 淳, 林 哲太郎, 藤井 慎介, 井上 省吾, 稗田 圭介, 神明 俊輔, 松原 昭郎
    超高齢時代の筋層浸潤性膀胱癌に対する低侵襲手術 ロボット支援根治的膀胱全摘除術 高齢者への導入 西日本泌尿器科 2018 80(4) 145-149
    Google ScholarIF:
  73. 小畠 浩平, 林 哲太郎, 藤井 慎介, 定秀 孝介, 後藤 景介, 岩本 秀雄, 井上 省吾, 大原 慎也, 加藤 昌生, 三田 耕司, 亭島 淳, 松原 昭郎 筋層非浸潤性膀胱癌に対するBCG療法におけるChronic Kidney Diseaseを用いた予後予測.泌尿器外科 (0914-6180)29巻4号 Page410-412(2016.04)
    Google ScholarIF:
  74. 亭島淳 林哲太郎 藤井慎介 井上省吾 稗田圭介 神明俊輔 松原昭朗.ロボット支援根治的膀胱全摘除術ー高齢者への導入—西日本泌尿器科別冊,2018,4月第80巻4号145-149.
    Google ScholarIF:
  75. 亭島淳 井上省吾 稗田圭介 神明俊輔 林哲太郎 松原昭朗.ロボット支援腎部分切除術〜症例などの最適な対応〜腎泌予防医誌 Vol.26,No1,2018 Mar,39-43
    Google ScholarIF:
  76. 林哲太郎 後藤景介 神明俊輔 井上省吾 亭島淳 松原 昭郎.膀胱癌のサブタイプ分類と分子標的治療への試み.西日本泌尿器科別冊,2017,79巻9号423-428
    Google ScholarIF:
  77. 亭島淳 井上省吾 池田健一郎 稗田圭介 神明俊輔 林哲太郎 松原昭郎 大原信也 加藤昌生 三田耕司.術前慢性腎臓病stageが腹腔鏡下・ロボット支援腎部分切除術の術後腎機能低下に及ぼす影響.西日本泌尿器科別冊,2017,79巻8号
    Google ScholarIF:
  78. 林 哲太郎, 井上 省吾, 亭島 淳, 松原 昭郎.【新腎・泌尿器癌(下)-基礎・臨床研究の進歩-】 陰茎癌 陰茎癌研究の歴史的変遷と展望 陰茎癌研究の歴史的変遷と展望(解説/特集) 日本臨床 (0047-1852)75巻増刊7 新腎・泌尿器癌(下) Page479-482(2017.10)
    Google ScholarIF:
  79. 福岡憲一郎、小羽田悠貴、松崎信治、栗村嘉昌、上野剛志、北野弘之、岩本秀雄、神明俊輔、稗田圭介、井上省吾、大原慎也、林哲太郎、亭島淳、三田耕司、繁田正信、松原昭郎
    化学療法未施行の去勢抵抗性前立腺癌に対する新規アンドロゲンレセプターシグナル阻害薬の治療成績(多施設共同研究)西日本泌尿器科.2017.79(8),333-8.
    Google ScholarIF:
  80. 金岡 隆平, 亭島 淳, 村田 大城, 定秀 孝介, 藤井 慎介, 小畠 浩平, 北野 弘之, 永松 弘孝, 岩本 秀雄, 瀬野 康之, 稗田 圭介, 神明 俊輔, 正路 晃一, 井上 省吾, 大原 慎也, 林 哲太郎, 加藤 昌生, 三田 耕司, 松原 昭郎.去勢抵抗性前立腺癌に対する新規ホルモン療法薬の効果予測(原著論文)泌尿器外科 (0914-6180)29巻8号 Page1283-1285(2016.08)
    Google ScholarIF:
  81. 馬場崎隆志、井上省吾、小畠浩平、重松慶紀、関野陽平、北野弘之、永松弘孝、稗田圭介、郷力昭宏、正路晃一、林 哲太郎、梶原 充、亭島 淳、松原昭郎. 低強度体外衝撃波によるED治療効果の検討-陰茎プレチスモグラフィを用いた客観的評価.西日本泌尿器科.2016,
    Abstract:パブメドGoogle ScholarIF:
  82. 林哲太郎、亭島 淳、松原昭郎. 特集:泌尿器科処方のすべて すぐに使える実践ガイド. 腎盂尿管癌. 臨床泌尿器科. 2016, 第70巻 第4号(増刊号), 172-174
    Abstract:パブメドGoogle ScholarIF:
  83. 林哲太郎、亭島 淳、松原昭郎. 特集:泌尿器科処方のすべて すぐに使える実践ガイド. 膀胱癌. 臨床泌尿器科. 2016, 第70巻 第4号(増刊号), 175-178
    Abstract:パブメドGoogle ScholarIF:
  84. 永松弘孝、亭島 淳、井上省吾、林哲太郎、松原昭郎. 特集:前立腺癌 前立腺癌とメタボリックシンドローム. 日本臨床. 2016, 第74巻・第1号別刷, 149-154
    Abstract:パブメドGoogle ScholarIF:
  85. 井上省吾、梶原充、馬場﨑隆志、小畠浩平、北野弘之、永松弘孝、稗田圭介、正路晃一、林哲太郎、亭島淳、松原昭郎. 単孔式腹腔鏡下副腎摘除術における整容性の縦断的解析. 西日本泌尿器科, 2015, 第77巻第11号, 391-397
    Abstract:パブメドGoogle ScholarIF:
  86. 北野弘之, 牟田口和昭, 郷力昭宏, 神明俊輔, 岩本秀雄, 林哲太郎. 筋層非浸潤性膀胱癌(Ta、T1) に対するBCG膀胱腔内注入療法の治療成績とEAUガイドラインのリスク分類の検討. 西日本泌尿器科. 2013, 75巻3号:107-113
    Abstract:パブメドGoogle ScholarIF:
  87. 柴田昌紀, 後藤景介, 林哲太郎, 池田健一郎, 稗田圭介, 正路晃一, 宮本克利, 増本弘史, 井上省吾, 小林加直, 梶原充, 松原昭郎. 転移性腎細胞癌に対するエベロリムス投与後に急性腎不全を来たした1例. 西日本泌尿器科. 2013, 75巻7号:383 -389
    Abstract:パブメドGoogle ScholarIF:
  88. 神明俊輔、高広悠平、柴田昌紀、瀬野康之、金岡隆平、稗田圭介、正路晃一、宮本克利、増本弘史、井上省吾、小林加直、林哲太郎、梶原充、亭島淳、松原昭 郎. 腹腔鏡下前立腺全摘除術における膀胱尿道吻合のV-Loc™180の使用経験. 西日本泌尿器科, 2012, 74(12): 682-685.
    Abstract:パブメドGoogle ScholarIF:
  89. 亭島 淳、池田健一郎、瀬野康之、小林加直、林 哲太郎、松原昭郎、小畠浩平・三田耕司、永松弘孝、藤原政治、角西雄一、中原 満、高広悠平、小深田義勝、上田晃嗣、長谷川泰久、水谷雅巳、吉野干城、森山浩之、望月英樹. 進行性腎細胞癌に対する薬物療法 ―ファーストラインの分子―標的薬―. 西日本泌尿器科, 2012, 24(11): 251-258.
    Abstract:パブメドGoogle ScholarIF:
  90. 梶原 充, 池田 健一郎, 岩本秀雄, 瀬野康之, 増本弘史, 小畠浩平, 郷力昭宏, 金岡隆平, 神明俊輔, 沖 真実, 正路晃一, 宮本克利, 井上省吾, 林 哲太郎, 小林加直, 亭島 淳, 松原昭郎. 腎細胞癌に対する単孔式腹腔鏡下根治的腎摘除術の安全性、有用性の検討 初期3例報告. 広島医学, 2012, 64(11): 489-493.
    Abstract:パブメドGoogle ScholarIF:
  91. 梶原 充、増本弘史、池田健一郎、井上省吾、柴田昌紀、稗田圭介、正路晃一、宮本克利、小林加直、林 哲太郎、亭島 淳、松原昭郎. 肝拳上用ポートを追加増設することなく Laparo-Endoscopic Single-Site Surgeryで右腎摘除術を行った3例. 広島医学, 2012, 65(9): 616-620.
    Abstract:パブメドGoogle ScholarIF:
  92. 亭島 淳、柴田昌紀、池田健一郎、稗田圭介、正路晃一、宮本克利、増本弘史、井上省吾、小林加直、林哲太郎、梶原 充、松原昭郎. 低・中リスク群限局性前立腺癌に対する密封小線源永久挿入治療の治療成績. 泌尿器外科, 2012, 25(8): 1655-1658.
    Abstract:パブメドGoogle ScholarIF:
  93. 小林加直, 柴田昌紀, 池田健一郎, 稗田圭介, 正路晃一, 宮本克利, 増本弘史, 井上省吾, 林 哲太郎, 梶原 充, 亭島 淳, 松原昭郎. 高齢者の筋層非浸潤性膀胱癌に対するBCG膀胱内注入療法の有効性と安全性. 泌尿器外科, 2012, 25(4): 753-754.
    Abstract:パブメドGoogle ScholarIF:
  94. 亭島 淳、井上省吾、稗田圭介、柴田昌紀、池田健一郎、正路晃一、宮本克利、増本弘史、小林加直、林哲太郎、梶原 充、松原昭郎. ロボット支援根治的膀胱全摘除術の初期経験. Jpn J Endourol, 2012, 25(2): 332-336.
    Abstract:パブメドGoogle ScholarIF:
  95. 梶原 充、増本弘史、井上省吾、柴田昌紀、池田健一郎、稗田圭介、正路晃一、宮本克利、小林加直、林 哲太郎、亭島 淳、松原昭郎. 肉眼的血尿をきたす薬剤. 臨床泌尿器科, 2012, 66(8): 541-545.
    Abstract:パブメドGoogle ScholarIF:
  96. 梶原充,池田健一郎,岩本秀雄, 瀬野康之,増本弘史,小畠浩平,郷力昭宏,金岡隆平,神明俊輔,沖真実,正路晃一,宮本克利,井上省吾,林哲太郎,小林加直,亭島淳,松原昭郎. 腎細胞癌に対する単孔式腹腔鏡下根治的腎摘除術の安全性,有用性の検討,初期3例報告, 広島医学, 2011, 64(11), 489-493
    Abstract:パブメドGoogle ScholarIF:
  97. 梶原充,金岡隆平,神明俊輔,瀬野康之,正路晃一,宮本克利,増本弘史,井上省吾,小林加直,林哲太郎,亭島淳,松原昭郎. 「頻尿・切迫性尿失禁」頻尿患者からどのようにして間質性膀胱炎を診断するか?(解説・特集), 臨床泌尿器科, 2011, 65(10) , 747-752
    Abstract:パブメドGoogle ScholarIF:
  98. 梶原充,後藤景介,稗田圭介,金岡隆平,神明俊輔,瀬野康之,正路晃一,沖真美,宮本克利,増本弘史,井上省吾,小林加直,林哲太郎,亭島淳,松原昭郎. 小児LUTSの診断と治療へのアプローチ 尿失禁・頻尿・夜尿症-泌尿器科医の立場から-, LUTS プライマリケア, 2011, 11 , 6-8
    Abstract:パブメドGoogle ScholarIF:
  99. 梶原充, 柴田昌紀, 後藤景介, 稗田圭介, 金岡隆平, 神明俊輔, 瀬野康之, 正路晃一, 沖真実, 宮本克利, 増本弘史, 井上省吾, 小林加直, 林哲太郎, 亭島淳, 松原昭郎. 【ちょっと気になる症候のみかた考え方2011】 夜尿,頻尿, 小児内科, 2011, 43(10) , 1784-1786
    Abstract:パブメドGoogle ScholarIF:
  100. 林哲太郎,松原昭郎. 特集-EAU/AUA/ASCOにおける泌尿器腫瘍のトピックス・進歩2011 尿路上皮癌, 泌尿器外科, 2011, 24(10) , 1629-1634
    Abstract:パブメドGoogle ScholarIF:
  101. 松原昭郎,亭島淳,林哲太郎,梶原充,小林加直,井上省吾. 大学病院として幅広く,高度先進医療を展開しつつ前立腺癌などでユニークな業績(Columu:林先生ーCAST法を用いた前立腺癌特異的な分泌膜蛋白質 の同定と機能解析), Corre Pon Urology(ファイザー雑誌), 2011, 64(2) , 1355-1363
    Abstract:パブメドGoogle ScholarIF:
  102. 林 睦雄、後藤景介、林哲太郎、井上洋二:上部尿路上皮癌に対するPluck法併用腎尿管一塊摘除術. Jpn J Endourol ESWL 23:231-238, 2010.
    Abstract:パブメドGoogle ScholarIF:
  103. 後藤景介、林哲太郎、井上洋二、林 睦雄:限局性前立腺癌に対する高密度焦点式超音波(HIFU)治療後のQOL. 西日泌尿 72:628-632, 2010.
    Abstract:パブメドGoogle ScholarIF:
  104. 後藤景介、林哲太郎、井上洋二、林 睦雄:尿路上皮癌の治療経過中に発生した膀胱小細胞癌の1例. 西日泌尿 72:697-700, 2010.
    Abstract:パブメドGoogle ScholarIF:
  105. 後藤景介, 林哲太郎, 井上洋二, 林 睦雄:長径10mm以上の上部尿管結石に対する治療戦略.広島医学 63(6):445-448, 2010
    Abstract:パブメドGoogle ScholarIF:
  106. 林 睦雄、後藤景介、林哲太郎、井上洋二:簡便法による後腹膜鏡下腎盂形成術の予後. Jpn J Endourol ESWL 22: 208-213, 2009.
    Abstract:パブメドGoogle ScholarIF:
  107. 林 睦雄、後藤景介、林哲太郎、井上洋二:根治的前立腺全摘除術後PSA failureで吻合部再発が疑われる症例に対する高密度焦点式超音波(HIFU)治療の経験.Jpn J Endourol ESWL 22: 301-308, 2009.
    Abstract:パブメドGoogle ScholarIF:
  108. 林睦雄、神明俊輔、林哲太郎、浅野耕助:簡便法による後腹膜鏡下腎盂形成術.Jpn J Endourol ESWL 21:165-171,2008
    Abstract:パブメドGoogle ScholarIF:
  109. 瀬野康之、奥谷卓也、井上省吾、林哲太郎、矢野明、田丁貴俊、藤井元広:前立腺導管癌の2例. 西日泌尿70(10):538-541,2008
    Abstract:パブメドGoogle ScholarIF:
  110. 瀬野康之、奥谷卓也、井上省吾、林哲太郎、矢野明、田丁貴俊、藤井元広:腹腔鏡下リンパ管遮断術を行った乳び尿症の2例.西日泌尿70(10):538-541,2008
    Abstract:パブメドGoogle ScholarIF:

受賞

2019年 第7回JSURT(泌尿器画像診断・治療技術研究会 京都市)Best poster award優秀賞 ▸ 尿管癌のCT grading systemは、腎尿管全摘除術の独立した予後因子である
2018年 16th Meeting of the IBCN (International Bladder Cancer Network,Rotterdam) ,Poster award ▸ Targeting HER2 with T-DM1, an Antibody-cytotoxic Drug Conjugate, is effective in bladder cancer with HER2 IHC score 2+/3+
2018年 日本泌尿器腫瘍学会第4回学術集会、学術集会奨励賞 ▸ 尿路上皮分化マーカーを用いた膀胱癌の免疫組織学的分類は、病理学的悪性度と予後を層別化し、治療方針の決定に有用となる
2017年 第69回西日本泌尿器科学会総会 学術奨励賞 ▸ HER2抗体-薬物複合体(T-DM1)はHER2を高発現する膀胱癌の新規分子標的治療となる
2017年 32th EAU Annual Congress (London), The EAU acknowledges the selection of the Best Poster in Poster Session 29:"Modern tools and new evidence in staging of urothelial carcinomas". ▸Prognostic impact of immunohistochemical classification of bladder cancer according to luminal(UroplakinⅢ) and basal(cytokertin 5/6)markers.
2016年 第68回西日本泌尿器科学会総会 学術奨励賞 ▸ DSC2は扁平上皮分化を示す尿路上皮癌の診断に有効で予後予測因子となる
2016年 31th EAU Annual Congress (Munich), The EAU acknowledges the selection of the Best Poster in Poster Session 10 entitled: Basic research in renal tumours: Looking for the right treatment for the right patient. ▸ TSPAN8 expression in renal cell carcinoma is a poor prognostic factor and a novel therapeutic target.
2016年 31th EAU Annual Congress (Munich), The EAU acknowledges the selection of the Best Poster in Poster Session 73 entitled: Scientific basis of experimental therapy in bladder cancer. ▸ STAT1 inhibition restored chemotherapy sensitivity in cisplatin/gemcitabine resistant bladder cancer.
2015年 第53回日本癌治療学会学術集会、優秀演題賞 ▸ 膀胱癌における新規HER2標的治療薬T-DM1の有効性
2015年 第103回 日本泌尿器科学会総会賞 ▸ Notch2は膀胱癌の進展を促進し、Notch2抗体療法は新規治療法として有望である
2014年 29th EAU Annual Congress (Stockholm), First Prize for the Best Abstract by a resident with a presentation in Poster Session 4 entitled: Molecular diagnostic and biomarkers of bladder cancer. ▸ Notch2 promotes bladder cancer progression: Pre-clinical rationale for a novel targeted therapy.
2014年 29th EAU Annual Congress (Stockholm), The EAU acknowledges the selection of the Best Poster in Poster Session 42 entitled: Novel experimental therapies and resistance in urothelial cancer. ▸ Targeting HER2 with trastuzumab-DM1 (T-DM1) is highly effective in preclinical models of HER2-overexpressing bladder cancer.
2012年 平成23年度広島大学学生表彰 ▸ DSC2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinoma.
2012年 平成23年度広仁会賞 ▸ Identification of transmembrane protein in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of CDON is involved in tumor cell growth and invasion.
2011年 第63回日本泌尿器泌尿器科学西日本総会 ヤングウロロジストリサーチコンテスト最優秀賞 ▸ The search for novel genes encoding secreted and transmembrane proteins in prostate cancer by the Escherichia coli ampicillin secretion trap.